Compare Globus Medical Inc. Class A Common Stock (GMED) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Starbucks Corp — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Starbucks Corp trades at $93.46 (market cap $104.88B). The key difference: Starbucks Corp is far larger — about 10.2× Globus Medical Inc. Class A Common Stock's market cap, and Starbucks Corp pays a 2.74% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Starbucks Corp for 190 Days on average.
| GMED | SBUX | |
|---|---|---|
Market Cap | $10.25B | $104.88B |
Volume | 1,108,124 | 9,749,448 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $108.55 |
52-Week Low | $58.33 | $79.60 |
Typical Hold Time | 0 Days | 190 Days |
Enterprise Value | $9.76B | $123.70B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SBUX trades at $93.25, up 1.05% on the day, amid a bearish technical signal and mixed fundamentals. Recent earnings show beats in Q1 and Q2 2026 but a miss in Q4 2025, with net income margin at 5.17%. The company is undergoing a strategic reset, closing 250 North American stores to optimize its portfolio, while facing headwinds from labor relations and geopolitical pressures in China.
The stock presents a cautious outlook with a high P/E of 53.18 suggesting premium valuation, yet analyst consensus targets $115.50 imply upside. Key risks include execution of store closures, competitive pressures, and macroeconomic sensitivity. Investor sentiment is divided, balancing restructuring potential against near-term operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
